Global Human Papilloma Virus (HPV) Testing Market to Reach US$1.6 Billion by 2018, According to New Report by Global Industry Analysts, Inc.

Share Article

GIA announces the release of a comprehensive global report on Cytology and HPV Testing markets. The global market for Human Papilloma Virus (HPV) Testing is forecast to reach US$1.6 billion by the year 2018, buoyed by rising global awareness about the close link between HPV and cervical cancer incidence. Intense Government measures and public awareness initiatives have made a substantial impact on the market for HPV Testing and immunization. Recent legislations to bring male population into the fold is a forward looking measure, and is expected to have a positive bearing on the long-term market outlook. In addition, growing awareness and acceptance of the HPV Test particularly in the underpenetrated developing markets will deliver robust growth performance.

Cytology and HPV Testing: A Global Strategic Business Report

Follow us on LinkedIn – Epidemiological and demographic transitions along with lifestyle changes are resulting in the emergence of cancer and other serious life threatening diseases. Accounting for about 12% of various types of cancers, cervical cancer is the second most prevalent forms of cancer affecting women all over the world. With over 150 million episodes per annum, cervical cancer represents one of the largest cancer screening opportunities for women worldwide, although only about 1.0% of such patients are actually diagnosed with the life threatening disease. In the context, the global Cytology and HPV Testing market is the largest as well as the most rapidly expanding segment in the field of molecular diagnostics. Long term infection with Human Papilloma Virus (HPV) is considered capable of causing abnormalities in the cells, thereby causing cancer of the cervix in absence of proper diagnosis or detection. Cervical cancer has a long latent period, of about 10 to 20 years for development and therefore, early detection and treatment of precancerous lesions would prove highly effective in women who regularly participate in the screening programs.

The untapped potential of HPV testing in prevention of cervical cancer, through regular screening programs in developed as well as developing countries, is manifested in various scientific studies. Currently, more than 1.0 million women world over have been successfully screened for Cervical Cancer using the technology, and there exists tremendous potential of HPV testing to prevent the onset of disease. The market for HPV testing is presently in a nascent stage of development, as actual acceptance rate and testing numbers continue to be severely deficient. Infact, penetration rates in the United States, which is the largest market for HPV testing worldwide, remain at just about 40%. On the other hand, growth potential appears stronger in developing markets, where a substantial 80% of new cases are reported annually and women are either affected or succumb to cervical disease or cancer each year. Majority of the deaths due to cervical cancer in these regions can be attributed to low awareness levels, poor diagnostic infrastructure, and little or no access to preventive tests or screening procedures.

In order to reduce incidence of cervical cancer, efforts are being intensified for popularizing HPV vaccine worldwide. With the realization that majority of cervical cancer cases are triggered by viruses of the HPV family, new and advanced opportunities for screening through the use of tests for HPV exposure have emerged in recent years. These screening methods have now entered the final stages of evaluation, primarily due to the availability of FDA approved standardized testing systems, which enable the detection of HPV DNA in exfoliated cells of the cervix. Also, epidemiologic and preventive efforts for cancer are being re-formulated around the world, as improved technology, new etiologic evidence and promising HPV vaccination measures become widely available. Cytological observation and HPV testing are considered two most conclusive and approved screening procedures for detection of HPV infections and cervical cancer.

The US Preventive Services Task Force (USPSTF) approved the HPV test as one of the most precise assessment methods as a part of the regular cervical cancer screening for women. The decision to make it a mandatory part of the cervical cancer screening process was finalized in the year 2012, after long-drawn state of ambiguity over HPV safety aspects. The cervical cancer screening guidelines issued by the American College of Obstetricians and Gynecologists in the year 2003 and the American Cancer Society in the year 2002, strongly recommend a combination of HPV test (HPV co-test) and a Pap test for all women above 30 years of age. In the year 2011, considering the benefits, the US government propagated and promoted the HPV vaccine for males in the age group of 11-12 years in an attempt to reduce instances of abnormalities caused by HPV.

The United States represents the single largest region in the cytology and HPV Testing market, capturing largest slice of the global market, as stated by the new market research report on Cytology and HPV Testing. In the US alone, about 80 million women were found to be at risk of developing cervical cancer, and accounts for about 11,000 cases of cervical cancer every year. However, despite the high number of cancer cases in the country, the situation is under control on account of the favorable and rigid counteractive measures adopted by the Government and medical authorities towards proper screening, diagnosing and immunization programs. In Europe, the other major market, HPV testing is increasingly gaining prominence as the most preferred primary screening method for determining the risk of cervical cancer in women. In specific Eastern European countries including Bulgaria, Romania, Latvia and Slovac Republic, primary cytology continues to be preferred to HPV screening despite the lower specificity and sensitivity limitations associated with it.

Key players profiled in the report include Abbott Molecular, Inc., BD Diagnostics-TriPath, CytoCore®, Inc., DaAn Gene Co., Ltd., Gen-Probe, Inc., Hologic, Inc., Third Wave Technologies, Inc., Merck & Co., Inc., QIAGEN NV, Qiagen North American Holdings, Inc., Roche Diagnostics, Ventana Medical Systems, Inc., and Roche mtm Laboratories AG.

The research report titled “Cytology and HPV Testing: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive industry overview, regulatory scenario, Reimbursement issues, market trends, HPV Vaccination, key growth drivers, recent industry activity, and profiles of major/niche global market participants. The report provides annual revenue estimates and projections for the years 2009 through 2018 in value terms for geographic markets including the US, Europe and Rest of World.

For more details about this comprehensive market research report, please visit –
http://www.strategyr.com/Cytology_and_HPV_Testing_Market_Report.asp

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.

Follow us on LinkedIn

Global Industry Analysts, Inc.
Telephone: 408-528-9966
Fax: 408-528-9977
Email: press(at)StrategyR(dot)com
Web Site: http://www.StrategyR.com/

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Public Relations
Visit website